Connect with us


Podcast: Keegan Peterson: Cannabis Industry HR and Payroll Solutions




Already Presented – Interview



Keegan recently joined our podcast host TG Branfalt … Read More…






Already Presented – Interview



Keegan recently joined our podcast host TG Branfalt for a conversation covering Würk‘s vision for the cannabis space and the major challenges and opportunities facing the industry, including high employee turnover rates, the slow but steady evolution of cannabis employee benefits, the importance of human resources and innovative payroll solutions, and more!

You can tune in via the media player below or scroll further down to find a full transcript of this week’s podcast episode.

Listen to the podcast:

Read the transcript:

Commercial: This episode of the Ganjapreneur Podcast is made possible by Evergreen Gateway, a provider of cannabis friendly financial services. As many cannabis entrepreneurs have experienced firsthand, it can be very difficult to get approval for essential financial services once your bank finds out what industry you’re in. Evergreen Gateway makes it easy for cannabis entrepreneurs to access the financial resources that you need to operate your business. From merchant accounts, to cash advances, virtual checking, and depository banking, Evergreen Gateway has established solutions that cater to the specific needs of the cannabis industry. Get in touch today at

TG Branfalt: Hey there, I’m your host TG Branfalt, and thank you for listening to the podcast, where we try to bring you actionable information and normalize cannabis through the stories of ganjapreneurs activists and industry stakeholders. Today I’m joined by Keegan Peterson. He’s the CEO of Würk, a cannabis-specific payroll and HR provider that advises in employee training, and performance management, and improving the employee experience, and wellness and benefits offerings. How are you doing this afternoon Keegan?

Keegan Peterson: I’m great, TG, thank you for having me today.

TG Branfalt: Hey, it’s super stoked. It is a real big sort of issue that’s emerged especially since cannabis 2.0 as some people called it in 2016, with California, Nevada, all that going online, massive markets. But before we get into those issues man, tell me about yourself. How’d you end up in the cannabis space?

Keegan Peterson: Yeah, so I’ve spent the last 10 years personally in the HR and payroll space outside of cannabis, working with predominantly the retail and restaurant industries. A friend of mine here in Colorado had a dispensary that had a hundred employees, and he had been dropped by his sixth payroll and HR provider because his company touched cannabis. And he reached out to me and said, “Keegan, you do this for a living, can you help me out? I just need to pay my employees. I need to pay my taxes.” At the time he was paying his taxes in cash. So he had to walk a million dollars of cash in a suitcase to the IRS building to pay his taxes at the end of the year. And that was a whole experience in itself. They had to have armed security guards on site, handcuffed the bag to his arm.

When he told me this story, I was like, my jaw was on the floor and I was like, this cannot be how this industry has to operate. So I quit what I was doing to help him figure out how to pay his employees and taxes, and then realized that the entire industry had a problem with this. So we started Wurk in 2015 to solve that problem so that every employee gets a paycheck, just like every other employee in the United States does, and to make sure taxes get paid on time and in the right format.

TG Branfalt: How many companies, and how many states are you currently providing services?

Keegan Peterson: We’re currently providing services in 33 legal cannabis states. And since the inception of our company, we paid over 60,000 employees, and the number of companies we service hundreds of companies and it’s growing every single day.

TG Branfalt: So there’s not really a state that you’re not in essentially. That’s massive. When you’re talking to employers, what have they identified as the biggest challenge in sort of the last few years, since more states have legalized medical and recreational cannabis, and how have they navigated these challenges?

Keegan Peterson: So the biggest challenge, we actually surveyed our customers very recently around this, and the number one challenge is growth. Last year, 2019, the biggest challenge with hiring. This year is growth. So I think both of those things are still big problems. This industry is growing very quickly, which means we need to hire a lot of people. The workforce isn’t there. We don’t have a huge workforce that has the experience necessary for cannabis. So everyone’s looking to other adjacent industries to find people. So it’s requiring to be very strategic on how you look and find and hire people, and the amount of resources you provide them to get them trained up to be successful in the business, to be happy at their jobs. So I think the trajectory we’re on, obviously it’s great for this industry and to see cannabis get to a point where it’s legalized and widely accepted is great, but it definitely requires a lot of people to get it there. And that’s putting a lot of strain on businesses.

TG Branfalt: When you said, the last time you surveyed was employment, this time it’s growth, aren’t these two things sort of linked.

Keegan Peterson: Yes, they are. I think now people are starting to, when they say growth, they’re starting to think about where my company is going to be in 12 months. A lot of times when people say hiring it’s because they haven’t been proactive about where the business is going, and they’re reacting by trying to hire as many people as possible. And therefore they’re hiring people that are just warm bodies, not necessarily folks that are grate for their company. But now businesses are starting to really think about where are we going to be in 12, 24, 36 months? What is it going to take to get there? How many people do we need to have on the team to be able to hit these objectives? What is the skill set? And then how do we go find the right people for the job? Or how do we train the people for the job? So I’m seeing a big shift in the industry from being reactive to growth, to being proactive in putting in good strategies.

TG Branfalt: So the single job, the average length of time spent at a single job in the cannabis industry is estimated at about one year. So with that sort of giant question mark, how can companies best retain and replace employees without just sort of putting in another warm body?

Keegan Peterson: Yeah, and to clarify that stat, that means that if the average length is one year, that means 50% of the industry had a turnover less than one year for every employee, and then the other 50% has a turnover more than one year. We did a survey and found that the month that is most likely for an employee to turnover is month four. So it’s important to understand how people come into your business, what they need, the reasons why they’re turning over, typically employees highest likelihood of turning over is because of the onboarding experience that you give them, which includes how you communicate with them, how you prepare them for their first day, making sure that all of their proper licensing and documentation is done ahead of time, making sure the training plan is in place to get them to be successful at their job.

Everybody wants to do a good job, but if you don’t provide them with the tools to be able to do a good job and just expect them to figure it out, that’s not a good plan. So the way that companies are providing a better experience for employees is really thinking about what does that first 30, 60, 90 days look like when someone comes into the company. What is the training and ongoing development path, that period of time. How are we continuing to provide career paths for the team members that we have, and how we provide training to get them through that career progression. And also, folks want feedback. So having some form of performance management in place so that people know I am doing a good job, I am not doing a good job, but here’s the thing that I need to do to do a good job. So it’s just really important to communicate with your team and make sure that you have some of these fundamental and foundational items in place.

TG Branfalt: So you mentioned turnover and I’m wondering sort of about this idea of a single job in the industry, and that sort of average being one year. Are people within that year moving on to maybe moving up, is there upward mobility in this space that sort of works hand in hand with this sort of lack of time spent in one job? Do you see a lot of people being promoted from within or is that a lot of outside stuff? What goes on there?

Keegan Peterson: Yeah, I think the number reason that folks are leaving their company, it’s compensation. Right now, we’re in a very competitive space. We have a limited market, we’ve got a limited access to a trained workforce. So folks that are high performers are very valuable and sought after by the industry, and so if someone down the road, a dispenser down the road is offering you a position for, even 50 cents more than what you’re making now, people are making that hop. So we’re starting to see compensation and the benefits offerings being much more important. But I do see organizations that are putting in good career progression and offering upward mobility, and those companies have a much lower turnover rate than other companies.

We’re so new in this industry and the opportunity to move up within a business really is infinite. And the more states that legalize, they’re looking for more folks that have that experience in the space. So I think this is an unbelievable industry to be a part of, it provides unlimited career progression, but people have to really sit down, spend the time, not only take advantage of the training that their company is providing, but also go out and research other training that would help them be a better professional, and constantly improve yourself, and I think the opportunities to progress are really infinite.

TG Branfalt: In a lot of legal States and in Canada, we’re starting to see sort of institutions of higher education offering programs, and you talk about training, are you seeing yet maybe businesses who are seeking people who have some of this sort of higher education formal training, or are these programs still too new, and the ideas too new that it’s on the forefront of owner’s minds?

Keegan Peterson: Yeah. I think, well I even got asked to go teach at university of Denver here in town. They have a couple of cannabis courses there. I think it’s too new for it to be something that folks are seeking out, just because they don’t necessarily know the training and skillsets that folks are getting in these courses. But as that matures and as we see more universities and higher education step in, I think that’s going to be a sought after skill, but the industry also is new in general. So a lot of these courses are still in the developmental stages. So I think that it will play a bigger role though, in the future. And I think the more training that people get both in the industry and in industries that are adjacent, it is where folks are going to be seeking talent.

TG Branfalt: Did you take the opportunity to teach at Denver?

Keegan Peterson: I try to, as many times. My schedule has been pretty challenging over the last several years since I started the company. But I’m hoping that this year when it comes to teach again then I’ll be able to mark out some time to make it happen because personally, that’s something I really enjoy is getting in front of this next generation of people coming into the workforce and getting them really excited for the opportunities before them. So, I’m looking for opportunities like that.

TG Branfalt: Yeah, I’m a college professor myself, and I don’t know anyone who’s taught any of those courses. So definitely hit me up if you end up doing that, but I-

Keegan Peterson: Yeah. What course do you, share with us, what course do you teach at what university?

TG Branfalt: …Oh, I teach media studies-

Keegan Peterson: What college?

TG Branfalt: …At SUNY Plattsburgh in upstate New York. So I teach about media bias and, we actually talk a lot about sort of the canna-bias in the media, in one of my classes.

Keegan Peterson: Very cool.

TG Branfalt: But media studies is boring compared to this.

Keegan Peterson: Yeah, but teaching like that’s very rewarding.

TG Branfalt: I love it. No, I definitely do.

Keegan Peterson: That’s proper chilled that.

TG Branfalt: So when we’re talking about HR, that’s something that obviously the payroll stuff companies are going to be on, on sort of that, but do they tend to overlook some of the other aspects of human resources when they launch their company? Are they deficient in some of those aspects when they launch? And what role does HR play in a company’s success?

Keegan Peterson: Yeah, I think it does, I don’t know if overlooked is the right word. Starting a cannabis business, the amount of work and compliance that goes into it is very, very overwhelming and more demanding than any other industry. So I think everything gets overlooked, not on purpose just by the sheer fact of there’s too much work to be done, but human resources play the major role in every single company as your center for compliance, and as your center for employee satisfaction, which employee satisfaction drives customer satisfaction. And your people are your product. If you’re a dispensary, your people are the ones that are out there in front of customers, sharing your story, showing the passion of the business, getting people not only excited for your company, but for the products that you’re offering, and also, they’re the ones that are properly educating your customers.

And then if you look all the way back in the supply chains to the folks when you grow, or the extraction lab, they’re the ones that are caring your plants, making sure that things happen on time and that your harvest sees all of its full benefits. And so people are a major, major asset to a company, and their first entry point into a business typically happens through the HR department. And it’s important to really think through what it means to be an employer. What responsibilities do you have? How do you give that experience to your team? How do you make sure that they are supported properly? And those things all add up to being a successful business and having customers that love you.

So the earlier folks start focusing on that, the more successful and the bigger opportunity they have to be successful. And a lot of times folks don’t necessarily have all the resources to drive that importance, and that’s were we’re trying to step in and not only provide technology to these businesses, but also provide additional services and consultants that are certified in the HR and payroll realms of business, and having those folks help these businesses get that foundational infrastructure in place.

TG Branfalt: What’s the first thing that you would tell a company that would come to you seeking the advice on HR specifically?

Keegan Peterson: Well, typically we ask for their handbook, because the handbook is a great place to see how they look at the business. And going through the handbook, we can see, okay, are we driving, when are we driving compliance in the business? And two, what type of experience are we giving to our team? And three, how are we providing benefits and opportunities for our team? And so I think that’s the place that we really start. And that’s where there’s a lot of opportunities to really think through what are the policies and procedures in the business to help employers be successful, to attract employees to come work for a business.

And then we start expanding from there. And then we start digging into those policies and procedures, and figuring out is this really best practice? Is this cutting edge? Does this really reflect the needs of the type of people that I’m trying to hire? And then we adjust. This is a new generation, a new workforce that has different things that they value, and businesses that are aware of that and provide that have much higher retention rate, have happier employees, and have a happier customer base. So yeah, that’s kind of how we work through the process.

TG Branfalt: Is there a figure that you guys sort of have, like how much it costs per employee to have to retrain somebody for that same position, time and time again, is there a dollar amount that’s on that?

Keegan Peterson: I’ve seen estimates of $2,000 per person, up to 4 to 5,000, and some folks up to 7,000 per person that turns over. And so when you break that apart, you think about, okay, now I don’t have this person to put out on the floor. So now my team if they’re already stressed and they’re potentially working into overtime, it costs me money and time to go find a new person that’s going to be a good fit for that company. Then we have to train that person and we have to onboard that person, and then they take time to actually get to be proficient at the job. So these are the big period of time there.

And there’s also time requirement from managers and other employees that all get wrapped into this cost of turnover. And when you think about companies that have a hundred percent turnover, and they have a hundred employees a year, we’re talking about serious money that’s going out the door, that can be avoided if you start thinking about, one, hiring the right people, two making sure we’re supporting the people and getting them onboarded properly, and then three, how we’re training and developing them over the course of their time with us, it makes a huge impact and your customer satisfaction, employee satisfaction, but it also makes a big impact on the bottom line.

TG Branfalt: When you talk about supporting, employee support, let’s talk about benefits for a minute, what do benefit packages look like in this space? Do they lag behind other, more mature and normalized industries? Or are they ahead of the curve as the industry is on some issues?

Keegan Peterson: Yeah, so it’s changed dramatically over the course of four years. Four years ago, everyone struggled to even get someone in the benefits world to speak to them. And now that the benefit providers who basically are sharing risk across all their customers, now that they have data on the cannabis industry and they realize that our workforce is young, they don’t self medicate with opioids, they’re using cannabis to have healthier lives, so they’re actually a really good risk pool for the benefits world. So over the last year to two years, we’ve seen a lot more of the carriers that are stepping in, it’s still limited, but we’re seeing much more normalized benefit plans.

I think there’s a real opportunity to think about what are the benefit plans for this industry, and what could be a potential new… what does the future look like for the benefits for the cannabis industry, and how do we craft that now and how do we do something very different than what’s being done today? And that’s where I think we can get ahead of the curve and be an industry that is changing the way that others think about helping their employees. But I’d say right now we’re really at a normalized state where we have some offerings, not enough, but we have some, and most folks have access to those.

TG Branfalt: So, sort of thing on this ahead of the curve thing, in New York cannabis industry employees are required to be part of a union. I know that other States have adopted similar, or in the process of considering in their legalization bills, this same sort of provisions, the same requirements. Does this unionization have an impact on HR and hiring practices in this space?

Keegan Peterson: Yes, of course it does have an impact and it requires organizations to now have potentially one or multiple different types of employee agreements in place, that they have to manage. But this is not uncommon from other industries. So we can pull from some of the experience of other industries on how we use technology, how do we use process and procedures to make these union contracts easier to manage. And that’s where I think technology does play a big role in this, because you could have a facility that has some employees that are a part of a union that have a specific benefits package and PTO policy and break policies, and that’s very different from your policy of the business, and how everybody else in the business has managed. So it’s important to have a technology provider that can help automate a lot of that, to make sure you are compliant. And that’s where I think that technology in the industry plays a major role in helping us stay compliant and manage some of the complexities that we’re are now starting to see.

TG Branfalt: So, and I got to ask, I mean, the questions I’ve asked you have been very sort of all over the industry, and you are very knowledgeable in each of them, and the industry is new and your sort of background is not in the cannabis space, it’s in the HR space. What was the learning curve life like for you? How did you make sure that you were covering all your bases getting into this industry?

Keegan Peterson: Yeah. So I’m a curious person, and my background was in big box retail. So I worked with companies like Target and PetSmart and Charlotte Russe. So I had a lot of experience in retail environments, and how they look at the business. I’ve had some experience in the supply chain, and how they get product to shelves. And then I spent some time in a restaurant space as well. The one thing that’s in common with all of those is the hourly workforce. So I have a skill set that applied well to the cannabis industry. And then I spent my first couple of months just trying to get out and visit businesses and learn as much as I could. Every time I went on a tour of a grower, I just asked question after question, learned about the plant, learned about how they thought about their business and how people moved and flowed in that business, and what were the challenges, and I noticed what was written on the wall and the whiteboards, and really tried to be a student. And that helped me quickly, personally understand what’s going on, and what were the challenges.

As far as starting the business, we’ve got a lot of lawyers that we work with. Employment lawyers, cannabis lawyers, corporate lawyers, tax lawyers, to really think through some of the specific use case in the cannabis space to make sure that, one, we’re properly supported and two, we can properly support our customers. So it’s taken a lot, and it’s an ongoing process. It’s not easy being in this space. It’s not easy being a service provider to this space because we have hundreds of customers that are all dealing with these challenges and their business change so frequently, and we have to manage, help vantage that with them. So it puts a lot of stress on what we do, but it’s work that we really enjoy doing.

TG Branfalt: And you don’t sound very stressed out man.

Keegan Peterson: I’m going my fifth year now in the cannabis space. So the anxiety is gone and my pain tolerance is significantly high, and I think that’s what it takes. But I love the work that we get to do every single day. It’s really special. This industry has really become my home. And there’s so much meaning to the work that we get to do, because we have customers, our customers have patients, patients now have access to a plant that changes a life for the better, and that’s great. I’ve been doing what I do for a very long time, but I have not been able to impact people’s lives like this before. So it’s just really special to be a part of this.

TG Branfalt: So my last sort of question is how much employment practices have on investments in the industry, and what are potential investors looking for with regard to employee company relationships?

Keegan Peterson: Yeah, it’s playing a much bigger role, especially with some of these big operators who are making headlines in the news for their employment practices. Employment practices are a part of the due diligence process. It’s part of the company, when investors invested in us, they asked about our employment agreements and our employment practices, it was a whole part of the diligence, and that’s pretty traditional in most industries. I think it’s been overlooked in the cannabis industry because people are so excited with the opportunity and everyone had the fear of missing out, but they moved very quickly. But now we’re seeing that the investors coming in are much more methodical about their approach to the space. And we’re obviously seeing a big cooldown and investment dollars coming in. And I think everyone knows that employee practices can also make or break your business.

So we’re seeing investors spend a lot more time understanding this side of the business. And we’re seeing businesses really think much more about this practicing as well. And a lot of folks that are going to go out and raise, or want to go be acquired, they realize that they need to have these things in place. They need to have good policies in place. They need to be able to track everything that they’re doing and show that they’ve been compliant so that investors are going to be interested in their business. So it’s great to see that this shift is happening because that means at the end of the day, employees get treated better. They have more resources. And I think personally, one of the things that I get really excited about this industry is the opportunity to shape an industry that is very inclusive, that is very diverse, that has employees that stick around forever.

If we can be the industry where the hourly workforce is attracted to, and wants to stay, and is proud to work in, I was thinking it would be such a gift. And it’s an obligation that we have, and it’s an opportunity that we have to really shape a different way of doing business. And that gets me excited, and it gets me excited to hear other entrepreneurs in the space that think the same way.

TG Branfalt: Yeah. I’ve always sort of thought about that, and then looking at sort of what’s happening with Canada, you have these massive companies that are doing these just huge layoffs, and there are some of the ones that were most heavily invested in, sort of cautionary tale for investors in many regards. What advice do you have for entrepreneurs, maybe sort of in your sort of lane or outside of your lane, you said you’ve been in this industry 15 years, what’s the first thing you tell somebody who says, “Now I want to start a cannabis business?”

Keegan Peterson: I think it’s important to really understand what you’re walking into and really understand what it’s going to take to be successful. This is not an easy industry to be a part of. I think there’s also this perception that everybody’s making money hand over fist here and that’s not the case. People that are in the space right now are folks that are really passionate about the plant and passionate about serving people. And that comes unfortunately right now as a sacrifice for most people, obviously we all see that one day, this industry will be treated fairly with taxes and it’ll be a good business to be a part of, but it’s going to take a while to get there.

And to run a cannabis business, it requires a lot of attention to detail, a lot of compliance and things that you don’t really necessarily have to deal with in other industries. So my advice to entrepreneurs is do a lot of research, spend a lot of time with folks that are doing it, really understand what you’re signing up for, and what it takes to be a successful entrepreneur in this space. And once you understand that dive in and make a difference in the world.

TG Branfalt: One thing, whenever I get you compliance guys on here, you guys always say attention to detail. It’s really like the number one thing, and it’s just something I’ve noticed that I’ve found interesting. Where can people find out more about you? Find out more about work? What you guys do?

Keegan Peterson: Yeah. Come check us out, our website is, and that’s work spelled with a U. Come check us out. We’ve got an office here in Denver. We’ve got an office in Scottsdale, Arizona. We’re opening up more. So yeah, come check us out and we’d love to have a conversation and help anybody we can.

Thank you for having me today. I really appreciate it, TG.

TG Branfalt: Thank you, Keegan, man. That’s really great to have you on, really insightful stuff, and I’ve been looking forward to this for a while because I think that it is an overlooked part of the industry that people are, again, they’re so excited that it sort of gets [inaudible 00:00:31:34]. So thank you so much. It’s Keegan Peterson, he’s the CEO of Wurk, a cannabis specific payroll and HR provider that advices employee training, performance management, improving employee experiences and wellness and benefits offering. Thanks again, Keegan.

Keegan Peterson: Thank you so much.

TJ Branfalt: You can find more episodes of the Podcast in the podcast section of and in the Apple iTunes store, on the website, you’ll find the latest cannabis news and cannabis jobs updated daily along with transcripts of this podcast. You can also download the app in iTunes and Google play. This episode was engineered by Trim Media House. I’ve been your host TG Branfalt.




Roger Adams and the Unexpected Discovery of CBD



The name Raphael Mechoulam has gained prominence in the last several years, as he is the man who first isolated delta-9 THC. Not as many people are familiar with the scientist Roger Adams, though he was just as important in the early research on cannabis. The story of Roger Adams and the unexpected discovery of CBD marks one of the biggest milestones in today’s cannabis research. Here’s how it happened.

Not everyone knows the name Roger Adams, or that he made the unexpected discovery of CBD. Just like not everyone knows what delta-8 THC is, or how it relates to marijuana. Both are very important. Roger Adams made some of the biggest discoveries related to identifying cannabinoids; and delta-8 THC represents what that research provided – an alternate form of THC which causes less psychoactive high, less anxiety, and less cloudy head. We support cannabis research, and all the great stuff that comes out of it. Check out our deals for delta-9 THCdelta-8 THC, and for a range of other minor cannabinoids like THCVTHCPdelta 10HHCTHC-O and more, to experience the outcome of decades of research!

Who is this Roger Adams?

Born in 1889, Roger Adams was an organic chemist from Boston, Massachusetts. Adams is from the same family as former presidents John Adams and John Quincy Adams, and is a direct descendent of John Adam’s grandfather. Adams attended Harvard University starting in 1903, and completed his undergraduate degree in three years. He went on to earn his PhD at Radcliffe College in 1912. He was such an outstanding student that he won the Parker Traveling Scholarship for 1912-1913, and used the money to work in laboratories in and around Berlin for that time period.

In 1913, Adams returned to the US, and began working as a research assistant, teaching organic chemistry at both Harvard and Radcliffe. He left the world of Harvard in 1916, upon accepting an assistant professor position at the University of Illinois, Urbana-Champaign. He remained at this university for 56 years. Adams spent the majority of this time as the department head for chemistry, taking the role from his predecessor William A. Noyes.

While working in this position, Adams accomplished several things. Together with students he created the Adam’s Catalyst, something used in hydrogenation reactions along with an apparatus for using this catalyst. He also elucidated the composition of complex vegetable oils and plant alkaloids. In the late 1930’s he began research into the cannabis plant and isolated the cannabinoids CBN and CBD, synthesized both, found delta-9 THC, and did a partial synthesis of that as well. He also synthesized analogues of these compounds. In this way, Roger Adams was the first guy to create a synthetic cannabinoid.

discovery of CBD, there’re two other guys who need to be mentioned, Thomas Easterfield and Robert S. Cahn. As science builds on itself over time, Easterfield’s and Cahn’s discoveries were what led into some of the bigger milestones in cannabis research. It all started with the desire to find what ended up being THC. In the search for the compound that caused intoxication, cannabis was first distilled into a ‘red oil’, which was the first form of it to be studied in modern times.

This red oil was discovered in the late 1800s by Doctor Thomas Hill Easterfield, a member of the Cambridge Group, who had been lecturing at Cambridge University at that time. In the late 1800s when he wrote about the red oil, he called ‘cannabinol’ a narcotic, which it was later clarified not to be by Cahn. At that time cannabinol was the main focus of the cannabis plant, first thought to be the intoxicating factor, but there was intense confusion around it.

Both the red oil, and the compound within, were given the name cannabinol. Though deeper questions were not answered at that time, cannabinol was the first cannabinoid to be isolated, and this was done by Easterfield.

All research was stopped, and Easterfield moved to New Zealand, following a couple incidents. One that involved the death of two collaborators in a lab accident, and one that involved the voluntary ingestion of a large dose of cannabinol by another collaborator, which led to the guy being out of his mind, and wondering around the lab as it caught fire around him. The fire was put out, and he returned to normal, but the news of these accidents was exaggerated and used in smear campaigns against cannabis, with claims that it was causing death and injury to researchers. This stymied research at the time, and it took about three decades for the next major breakthrough, brought by Robert Cahn.

In the 1930s, Doctor Robert S. Cahn began studying the structure and bioactivity of CBN. Cahn called the red oil ‘crude cannabinol’. He used the name ‘cannabinol’ specifically for the pure compound within the oil which he was able to show did not have intoxicating properties, ending the idea that CBN was the psychoactive constituent of the plant. Cahn was able to map the structure of CBN, using the relative position of specific atoms and groups of atoms within the compound, but there were still several questions that didn’t get ironed out until Roger Adams and Alexander Todd began studying the compounds later that decade.

Roger Adams and the unexpected discovery of CBD

The whole idea with the research previous to Adams, was to locate the intoxicating element of cannabis, which was first thought to be cannabinol. Roger Adams began his research into cannabis after the Marihuana Tax Act was passed in 1937, meaning he couldn’t legally study the plant anymore, and had to receive authorization to do so. Prior to getting into cannabis research, Adams had been studying biphenyls and their atropisomerism. What this means is less important for our purposes, than the understanding that cannabinol is a biphenyl derivative, meaning Adams was already well versed in compounds similar to cannabinol, and this made him a great choice to study it.

Hemp-derived Delta 9 THC

It was actually the Bureau of Narcotics of the US Treasury Department which requested Adams do the research into cannabinol, in an effort to locate and isolate the intoxicating element. Funny enough, it was the general misunderstanding about cannabis at the time, that led to the confused discovery of CBD.

You see, cannabis was not well understood, and instead of providing Adams with high-THC cannabis (marijuana), he was provided with high-CBD cannabis (hemp). Using hemp to study THC is much harder, as there is considerably less of it there. THCA is the precursor to CBN, and it only exists in small amounts in hemp, whereas CBDA is more prevalent, but is the precursor to CBD, not CBN. This made it very difficult for Adams to isolate the already-known-about CBN from the plant.

It was this attempt to isolate CBN from the red oil which led Adams to try different methods of isolation. He could not get a direct crystallization of CBN by acetylation (a specific kind of chemical reaction). He instead tried other reagents, eventually finding himself with a previously unidentified crystalline substance. This substance ended up being CBD. In order to isolate the CBN, Adams had to go through a process of purification from the crystalline CBD, which means Adams had to identify a new cannabinoid, in order to isolate the one already found.

What about Alexander Todd?

The story of the discovery of CBD, is twofold. Though Roger Adams is the one who gets credit, there was a parallel discovery around the same time, and that was made by British chemist Doctor Alexander Todd. The two scientists were rather competitive in the late 1930’s and early 1940’s, each publishing their discoveries as they came across them, and likely spurring each other on to work harder and do more.

There was even some contention between them as they both raced to find the same thing – THC, and though neither did find it, they did identify the other major component of the plant. In later years they actually became friends and formed a partnership, but I expect the competitive nature between them is what sped up the discoveries they made.

Anyway, Alexander Todd is more notorious for his winning of a Nobel prize for his work with nucleotides, but before this happened, he got into studying cannabis at the relatively young age of 32. He worked out of the University of Manchester with a very small research group, but was still able to isolate CBD from a sample of Indian hash. The hash had to be carefully gotten to him, as cannabis was illegal in Britain starting in 1928. When he published his paper in 1940, Todd was required to register at the Home Office for holding 2.5kg of hash.

These two scientists exemplify the often meandering line it takes to get from point A to point B in scientific research. And though neither reached the goal of finding the intoxicating agent, in attempting to do it, they both became pioneers in the world of cannabis research. Together, yet separately, they discovered one of the main aspects of the cannabis plant.


It’s quite possible that Roger Adams and the unexpected discovery of CBD was very much helped along by his rivalry with Alexander Todd. Either way, neither scientist reached the goal of isolating THC, though Roger Adams was able to identify it. It took another 25 years until Raphael Mechoulam finally did the job in 1964.

In a way, CBD was found completely accidentally. Though it would likely have been discovered at some point, it wasn’t even conceived of at the time it came to light. Roger Adams and Alexander Todd were trailblazers when it came to cannabis research, paving the way for Mechoulam, and the industry as we know it today.

Hello all! Thank you for joining us at, the best online location for the most up-to-date and cutting-edge cannabis and psychedelics-related news from around the globe. Drop by regularly to stay abreast of the ever-changing universe of legal drugs and industrial hemp, and sign up for our newsletter, so you always know what’s going on.

DisclaimerHi, I’m a researcher and writer. I’m not a doctor, lawyer, or businessperson. All information in my articles is sourced and referenced, and all opinions stated are mine. I am not giving anyone advise, and though I am more than happy to discuss topics, should someone have a further question or concern, they should seek guidance from a relevant professional.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.


Continue Reading


Albert Hofmann: The Finding and Self-Experimentation of LSD



The psychedelic boom is just beginning, with legalizations occurring, and new bills working their way through local governments to provide more psychedelic freedom. For those still unaware, psychedelics have been proving to be a valuable medicine in the fight against mental illness. When looking back in the history of medical psychedelics to where it started, it all comes down to one man, Albert Hofmann, and his discovery of LSD.

Albert Hofmann sure started something big when he discovered LSD, but it might be a while longer before LSD is legalized. If psychedelics continue like the cannabis industry, it should happen eventually. Luckily, for now we’ve got cannabis, and all its great medicinal and recreational compounds, like delta-9 THC, delta-8 THC, and a range of other minor cannabinoids like THCV, THCP, delta 10, HHC, THC-O and more. You can go ahead and check out our weekly deals.

What are psychedelics?

Psychedelics are drugs that contain chemical compounds that cause a psychoactive reaction in a user. Such reactions include experiencing hallucinations, which means hearing, seeing, feeling, tasting, and smelling things that aren’t there. Psychedelics are also associated with creating spiritual experiences and can promote feelings of connectedness between the user and others around. Users experience euphoria, relaxation, and well-being, while also experiencing mystical sensations. Psychedelics can alter mood, perception, and cognition, though different drugs can cause different effects, and the amount taken is important.

Psychedelics are a subset of hallucinogenic drugs, which themselves are a subset of psychoactive drugs. They can be found in nature, like magic mushrooms or peyote, or made in a lab like LSD or PCP. Though psychedelics have been found generally safe in testing, getting the dose correct is important. This is the same with any type of medication, and is not specific to psychedelics. A person who takes too much oxycontin might overdose and die, a person who takes too much LSD might have a bad trip.

‘Bad trips’ are characterized by negative, or even scary, hallucinations. Users can experience feelings of dysphoria, anxiety, and panic, as well as physical symptoms like dizziness, irregular heartbeat, numbness, vomiting, and sweating and chills. Bad trips have not been known to result in death, but can certainly be a negative experience for the user, and back up that careful dosing is very important.

Albert Hofmann LSD

Many psychedelics are serotonergic, meaning they interact with serotonin receptors in the brain. This will usually cause a rush of the neurotransmitter, followed by blocking reuptake to allow for more absorption. The neurotransmitter serotonin is responsible for many functions in the human body, from mood regulation and involuntary muscle control, to transmitting signals throughout the brain.

Historical use of psychedelics

Though we treat psychedelics like we don’t know much about them in mainstream life, there is plenty of evidence they’ve been used for thousands of years, although the context they were used in, may have been different from how they’re used today. Information that we do have was obtained from ancient texts, findings, and rituals.

For example, in the Sora River Valley of Southwestern Bolivia, a pouch was found containing traces of different psychedelic compounds including both harmine and dimethyltryptamine – used to make ayahuasca; bufotenine, a psychedelic compound found in toad skin; and psilocin, a psychedelic compound of magic mushrooms. The pouch is said to be from around 900-1100 CE according to mass spectrometry carbon dating. This is the earliest finding to show the use of the plants that combine to make ayahuasca.

Other research has pointed to use of psychedelics in Mesoamerica by the Mayans, Aztecs, Olmecs, and Zapotecs. The Mayans were known for drinking balché from Lonchocarpus bark extracts, which together with honey produces a psychoactive effect (the bark can itself, but is milder without the honey). It was used for group ceremonies to get intoxicated. The cultures mentioned used the peyote plant for mescaline, hallucinogenic mushrooms, and ololiuhqui seeds, which contain lysergic acid amide, a relative to LSD.

The near-East has also been a hotspot for ancient psychedelic findings. Several artifacts have been made in that region including residues, fibers, pollen, and carbonized seeds. In fact, traces of Blue Water Lily extract, a strong narcotic, were found in Tutonkamen’s tomb which dates back to the 14th century BC. In Lebanon, 10 liters of Viper’s Bugloss was found in a storage jar in Kami del-Loz temple from the late bronze age. Viper’s Bugloss is a very strong hallucinogenic compound.

What led up to Albert Hofmann finding LSD

History is all fine and good, but in today’s world we study things in labs. In modern times, the practice of studying psychedelics began in Switzerland with a chemist named Albert Hofmann. Born in 1906, in Baden, Switzerland, Hofmann finished his chemistry degree at the University of Zurich in 1929. Immediately after graduation, he began working for the chemical company Sandoz.

When Sandoz hired Hofmann, the company had only opened a pharmaceutical department a few years before in 1917, even though the company was founded in 1886. The pharmaceutical department started with the isolation of a compound called aotamine from a fungus called ergot, which can be found in tainted rye. Ergot has been used in natural medicine traditions for many, many years, since in small doses, it has been known to quicken child birth, as well as help with the bleeding after. However, when found in tainted rye, ergot can cause incredible illness. The scientist who isolated the compound, Arthur Stoll, wanted to isolate the part that caused the constriction that allowed for the medical advantages only.

He was able to do it, isolating the compounds ergotamine and ergobasine, which enabled the ability to dose very precisely, and without other compounds from ergot getting in the way. Within the next few years, researchers at the company were able to elucidate the chemical structures of different compounds of ergot thought useful, all of which share a common nucleus. This point at which all the compounds start, is named Lysergsaure (in German), or lysergic acid. These discoveries made a lot of money for Sandoz, and helped launch a pharmaceutical department for further research and development. This is the climate that Hofmann walked into when he was hired in 1929.

Albert Hofmann and the unexpected finding of LSD

When Albert Hofmann entered the picture, the Sandoz lab was busy studying ergot, and the compounds within. Hofmann was able to establish a synthetic process to build the ergot compounds using the chemicals that make them up. He was able to synthesize active components of ergot, along with similar compounds from other plants, that were thought to be possible for medical use. Hofmann did a lot of experimentation, combining lysergic acid with other compounds to see what kind of results occurred. He did this about 24 times before something big happened.

Hofmann had been trying to find a combination that could stimulate circulation and respiration. On the 25th occasion of combining lysergic acid with another compound, Hofmann used diethylamine, a derivative of ammonia. The compound it created, was called LSD-25 at the time, or lysergic acid diethylamide. Though it did not meet the needs specifically of what he was looking for, it was noted that the created compound caused excitability in animals during testing. At the time, LSD-25 was put on the backburner, but Hofmann couldn’t forget about it, saying it was “a peculiar presentiment—the feeling that this substance could possess properties other than those established in the first investigations.”

Five years later, he felt the urge to recreate this compound again, and this time, something very strange happened. He started feeling strange. It was a Friday, so he left the lab early and returned home. When he came back into the lab the following week, he wrote this to Stoll, who was his boss at the time:

“I was forced to interrupt my work in the laboratory in the middle of the afternoon and proceed home, being affected by a remarkable restlessness, combined with a slight dizziness. At home I lay down and sank into a not unpleasant intoxicated-like condition, characterized by an extremely stimulated imagination. In a dream-like state, with eyes closed (I found the daylight to be unpleasantly glaring), I perceived an uninterrupted steam of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colors.”

What did he do next?

When Albert Hofmann first discovered the effects of LSD, he didn’t know what caused them. First, he thought he had been exposed to some kind of chloroform solvent, but when he intentionally breathed in fumes, he didn’t get the same response. It finally occurred to him that he might have actually ingested some of the LSD-25 he was working with, despite the fact that the only place he had made contact, was his fingertips. As it was understood ergot compounds could be toxic, a lot of measures were taken for safety. Upon realizing it might have been the LSD-25, Albert Hofmann did what any good scientist would do, he began experimenting on himself.

On April 19th, 1943, Hofmann dissolved 250 millionths of a gram of lysergic acid diethylamide tartrate (the crystalized version of LSD-25), and drank it down. He did this without giving a heads up to anyone at Sandoz except his lab assistant, and he didn’t expect anything to happen. He had taken such a small dose – with the intention of slowly increasing to find the right amount, that he hadn’t expected the response that he got. After about 40 minutes, he wrote this:

“Beginning dizziness, feeling of anxiety, visual distortions, symptoms of paralysis, desire to laugh.” Due to his condition, he had to have his lab assistant take him home, which due to wartime restrictions, meant riding on bikes. One can only imagine how funny that bike ride must have been! He later said this about the experience:

“Everything in my field of vision wavered and was distorted as if seen in a curved mirror. I also had the sensation of being unable to move from the spot. Nevertheless, my assistant later told me that we had traveled very rapidly. Finally, we arrived at home safe and sound, and I was just barely capable of asking my companion to summon our family doctor and request milk from the neighbors.”

Though the symptoms were frightening, as they were unexpected, a doctor’s visit confirmed that nothing was actually wrong with Hofmann. When he had calmed down, and could speak clearly about his experience, he said this: “Everything glistened and sparkled in a fresh light. The world was as if newly created. All my senses vibrated in a condition of highest sensitivity, which persisted for the entire day.”

Hofmann continued experimentation with himself and a couple close friends. He found the setting to be a very important factor in how the trip played out. Hofmann went on to introduce this new compound to psychiatrists in the mid-1900’s like Humphry Osmond and Ronald Sandison. Osmond conducted the Saskatchewan trials in Canada. In the studies, alcoholics were given LSD to quit drinking, and according to the studies, an entire 40-45% were able to do so for at least a year after only one dose. Sandison operated out of the UK, doing his own experimentation with acid. One of his experiments included using 36 psychoneurotic patients, all of whom were cured or showed improvement after using LSD, save for two. Both doctor’s developed their own strategies for the emerging psychedelic-assisted therapy, all based on Hofmann’s experiences.

Albert Hofmann LSD


The story of acid is obviously much longer than this, but this is how it started, with Albert Hofmann and his self-experimentation of LSD. Though LSD is currently Schedule I in the US, both psilocybin and MDMA have been designated by the FDA as breakthrough therapies, and Oregon has already legalized psilocybin for medical purposes. On top of that, esketamine, a close relative of ketamine, is already approved for depression and suicidal thoughts, and is in use in clinics all over America.

LSD is a synthetic psychedelic compound, though it has roots in the ergot plant. While it was the most commonly used medical psychedelic in the mid-1900’s, it was illegalized and demonized shortly after, only now gaining attention once again for its medical benefits. With the impending legalization of other psychedelics, one can only imagine that LSD will be coming soon too.

Welcome to, your premiere location for the most current and thought provoking cannabis and psychedelics-related news worldwide. Check out the site daily to stay abreast of the quickly-moving world of legal drugs and industrial hemp, and don’t forget to sign up for our newsletter, so you always know what’s going on.

DisclaimerHi, I’m a researcher and writer. I’m not a doctor, lawyer, or businessperson. All information in my articles is sourced and referenced, and all opinions stated are mine. I am not giving anyone advise, and though I am more than happy to discuss topics, should someone have a further question or concern, they should seek guidance from a relevant professional.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.


Continue Reading


The Economic Impact of Cannabis | Cannabiz Media



Be the first to know when new content like this is available!

Subscribe to our newsletter to get alerts about new posts, local news, and industry insights.

Research and economic data collected in recent years shows that the cannabis industry positively affects the economies in states and municipalities by creating more jobs, increasing real estate values, and generating tax revenue that is used for a wide variety of purposes. 

Employment Benefits from the Cannabis Industry

With the opening of cultivation facilities, manufacturing facilities, dispensaries, and retail stores to support the legal cannabis industry, jobs are created. In addition to jobs that are directly involved with the marijuana supply chain, there are hundreds of ancillary jobs needed to keep the industry going. These include accountants, lawyers, and many more.

It is estimated that the legal cannabis industry employed 321,000 full-time workers across the 37 states in the United States with operational medical and/or cannabis programs as of January 2021. Of those full-time jobs, 24% (77,000) were added during 2020 showing a significant growth trend as more states launch and expand cannabis programs.

When you add in the estimated eight to 10 ancillary businesses that are thought to support every one licensed cannabis company, the employment numbers skyrocket. Based on this data and future predictions, it’s clear that regulated cannabis markets benefit states’ economies by creating thousands or tens of thousands of new jobs.

Real Estate Benefits from the Cannabis Industry

States that have legalized medical and/or recreational cannabis are seeing a significant increase in property values and lease rates where licensed cultivators, manufacturers, dispensaries, and retailers can operate. 

Due to strict zoning laws in many areas, marijuana businesses have a limited supply of properties to choose from to build their facilities. Property owners understand this and face their own risks when they rent to cannabis-related businesses. As a result, lease rates and property values skyrocket.

It’s not just commercial property and land values that benefit from the marijuana industry. A study of Colorado municipalities published in January 2018 found that housing values increased by 6% with cannabis legalization.

Tax Benefits from the Cannabis Industry

One of the easiest ways to track the economic benefit of the legal cannabis industry to states and local municipalities is through tax revenue, particularly in states that have legalized both recreational and medical cannabis since adult-use taxes are typically much higher than medical taxes. In fact, some states don’t tax medical cannabis at all, but it’s not unusual for adult-use cannabis to be taxed multiple times (excise tax, state sales tax, and local tax) and at rates as high as 15%, 17%, or even 37%.

How much do all of these taxes bring in for states? According to Motley Fool, California brought in $1,031,879,926 in tax revenue in 2020 – the most of any state. In Washington State, tax revenue in 2020 reached $469,200,000, and in Colorado, 2020 tax revenue was $387,480,110. 

Taxes collected by states and local municipalities are used for a variety of purposes – from funding community programs, education, and law enforcement to paying for the costs to run the state or town’s cannabis program.

The Cannabis Industry Provides a Positive Economic Impact

When a state allows the sale of medical and/or recreational cannabis, its economy benefits. That’s the conclusion numerous researchers have made after analyzing a number of economic factors over the past several years. Specifically, employment rates, real estate values, and tax revenue all increase with the approval of medical and adult-use cannabis.

MJBizDaily reported economic data in its 2021 Annual Cannabis Business Factbook that puts the economic impact of a legal cannabis market into perspective. Consider these facts:

  • Total U.S. economic impact from cannabis sales in 2021 is expected to reach $92 billion (up more than 30% from 2020).
  • Total U.S. economic impact from cannabis sales will increase to upwards of $160 billion in 2025.
  • For every $1 consumers and patients spend at retail locations, an additional $2.50 will be injected into the economy – much of it at the local level.
  • California’s legal cannabis industry is expected to add nearly to $20 billion to the state’s economy in 2021.
  • Legal cannabis markets in Colorado, Illinois, Oregon, and Washington will each add more than $10 billion to their local economies in the coming years.
  • Nevada’s economic impact per person from the legal cannabis industry will be approximately $1,917 in 2021.
  • Legal cannabis markets in Alaska, Colorado, and Oregon will each deliver approximately $1,500 per person into their economies this year.
  • California will deliver an estimated economic impact per person of $500 in 2021.

Bottom-line, the data shows that the cannabis industry has a positive economic impact on states and communities, and that impact hasn’t peaked yet.

Originally published 11/13/18. Updated 9/24/21.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.


Continue Reading


CBD (Cannabidiol) Explained – The Real Benefits of this Trendy Cannabinoid



While a fringe, alternative treatment option only a decade ago, today, CBD is everywhere you look – in wellness supplements, beauty and hygiene products, FDA-approved prescription medications, food and beverages, dental products, and even pillows, mattresses, and other random household goods.

As far as cannabinoids go, CBD, or cannabidiol) is the most widely accepted. Not only is there a growing body of clinical research to support its benefits, but it is non-intoxicating which makes it much more likely for laws to be passed in its favor – as is evidenced by the fact that CBD is federally legal in the US and many other countries, while THC still is not. But when it comes to CBD, what are some actual legitimate uses for this compound, and which ones are just marketing gimmicks? Let’s take a look at some of the real, science-backed benefits of CBD.

CBD is amazing, and so incredibly versatile. To learn more about this compound, and for exclusive deals on CBD flowers, as well as on Delta 8Delta 10 THCTHCVTHC-OTHCPHHC and even on legal Delta-9 THC! , make sure to subscribe to The CBD Flowers Weekly Newsletter, your hub for all things CBD-related.

What is CBD?

CBD, or cannabidiol, is the most prominent, non-intoxicating compound found in cannabis plants. When most people think of cannabis, they’re thinking about marijuana, which is the type so cannabis that is high in THC and associated with feelings of being “stoned”. Some types of cannabis, hemp for example, are high in CBD and contain only trace amounts of THC, meaning these plants can be considered non-intoxicating, by all accounts.

CBD is gaining popularity as a safe, non-toxic, non-addictive, natural treatment option for many different chronic and debilitating ailments; both mental and physical. Not only is CBD itself non-psychoactive, but when taken in combination with compounds that are, like tetrahydrocannabinol for instance, CBD can minimize the likelihood of negative side effects such as paranoia and anxiety that are occasionally associated with THC use.

The reason CBD (or any cannabinoid for that matter) works in the human body at all is because of the Endocannabinoid System (ECS) – a complex signaling system made up of numerous receptors, as well as some naturally produced endocannabinoids, that exists in the bodies of nearly all animals (except insects). Researchers have discovered two different endocannabinoids so far, 2-arachidonoylglycerol (2-AG) and anandamide (AEA), plus the two most studied receptors, CB1 and CB2. This quad makes up the majority of existing cannabis research.

As a whole, the ECS regulates numerous different functions and processes in our bodies and maintains internal balance and homeostasis. Many cannabinoids engage directly with the ECS receptors. Others, like CBD, have indirect connections by activating other receptors that will then interact with the endocannabinoid system. Specifically, CBD activates the TRVP1 receptors, which in turn activate receptors in the ECS and also function as ion channels.

CBD as an Anti-Inflammatory

One of the most common uses for CBD is to treat inflammation, which is the body’s process of fighting against pathogens and other hazards, such as infections, injuries, and toxins. When something damages your cells, your body releases chemicals that trigger a response from your immune system, thus causing inflammation.

The phrase “too much of a good thing” really applies in the case of inflammation. When this inflammatory response lingers after your body is done fighting the infection or whatever it is trying to overcome, this leaves your body in a constant state of stress and unrest. Chronic inflammation can have devastating effects on the tissues and organs and research indicates that it’s the root cause of many ailments including arthritis, contact dermatitis, acne, multiple sclerosis, and type 1 diabetes, asthma, and cancer.

Cannabidiol is becoming a very popular alternative for standard NSAID (Nonsteroidal anti-inflammatory drug) drugs like Aspirin. Long-term use of NSAIDs can lead to various health problems such as heartburn, stomach pain, ulcers, headaches, dizziness, and even damage to the liver and kidneys.

CBD to Manage Anxiety

Anxiety is another condition that’s been researched extensively to determine how well it responds to cannabis therapies. Cannabidiol targets cell receptors in the body and brain that regulate your mood. Many mood disorders, including anxiety and depression, have a few things in common, including a lack of naturally produced endocannabinoids.

Treating mood disorders with CBD is becoming more widespread is among the top-rated treatment options for young adults ages 25-40. According to a study conducted a couple of years ago, thirty-four percent of millennials prefer to manage their mental health with natural and holistic remedies, and 50 percent of millennials believe CBD oil is the best way to do this; and this number continues to grow.

The main reason cited was a fear of being prescribed a medication that is too potent for their level of symptoms. Because CBD doesn’t have the mind-numbing and other unwanted side effects of prescription drugs, nor is it psychoactive like THC, it can be used all day like any other medication or supplement.

CBD for Controlling Seizures

One of the first, medically-accepted, modern-day uses for CBD was to treat epilepsy. There are many studies out there researching its effectiveness. As a matter of fact, there is even an FDA-approved, cannabidiol-based medication, Epidiolex, that’s used to treat two rare and severe forms of childhood epilepsy, Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).

Epidiolex is currently being prescribed in the United States, many countries in Europe, and Japan. Epilepsy medications can have some very serious side effects, and that’s why more natural alternatives are becoming the go-to ­­way to treat children and younger adult patients who suffer from epilepsy.

CBD for Pain Management

Although not common, many patients turn to a CAM, or complementary alternative medicine approach, to manage chronic pain. CBD is at the top of the list for those looking for natural, yet effective, alternative remedies. Because inflammation is the root cause of so many conditions that cause chronic pain, it makes sense how CBD eliminates pain.

Numerous different studies have found that cannabinoids like CBD can help with chronic pain from multiple sclerosis, cancer, and neuropathy. CBD and CBD topicals help with pain — if you suffer from chronic pain, CBD oil may help, as well. Chronic pain can be the main source of a diminished quality of life — CBD may give you hope for getting pain-free, or at the very least, reduced pain, and anything is worth a try.

CBD for Skin Conditions

Studies have shown that CBD can provide relief for the symptoms of various skin disorders, such as eczema and allergic reactions. Reverting back to ​inflammation, we know that cannabidiol can be used internally inflammatory conditions, and now we also know that it does the same when applied topically.

Topical creams containing CBD have been shown to ​or greatly reduce and sometimes even completely eliminate itching and dryness​ ​in sufferers of eczema. The chemical ‘histamine’, which is largely responsible for the irritating itches we experience, has been shown to react well to topical cannabinoid therapy. One study​ ​found that in almost 59% of its participants, their dry and scaly skin significantly reduced with the regular use of a cannabinoid cream, which reduced itching and as a result lead to less sleep loss.

Final Thoughts on Cannabidiol Benefits

Simply put, cannabidiol is an incredible compound. It’s non-psychoactive, non-toxic, and non-addictive; and it can be used to treat dozens of different health conditions. The ones covered in this list are the most common uses for CBD, but it can be utilized for many other ailments as well. Do you use CBD? And if so, what do you use it for? Drop us a line in the comment section below!

Thank you for stopping by CBD TESTERS, your hub for all things cannabis-related. To learn more about weed, and for exclusive deals on flowers, vapes, edibles, topicals, and other products, make sure to subscribe to The CBD Flowers Weekly Newsletter.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.


Continue Reading
Esports5 days ago

How to start a Private Queue in CS:GO

Esports4 days ago

Can You Play Diablo II: Resurrected Offline?

Esports4 days ago

How to complete all week one missions in Operation Riptide

Esports4 days ago

Failed to Enter Game, Character Could Not be Found: How to Fix Error in Diablo II: Resurrected

Esports4 days ago

Valkyrae says YouTube is working on gifted members and a feature similar to Twitch Prime

Esports2 days ago

Fall Guys achieves Guinness World Record for most downloaded PlayStation Plus game ever

Esports4 days ago

Valkyrae says YouTube is working on gifted members and a feature similar to Twitch Prime

Esports5 days ago

Initial reactions to the Worlds 2021 group draw: How does each team stack up against the field?

Esports5 days ago

Pokémon UNITE APK and OBB download links for Android

Esports3 days ago

Microsoft’s The Initiative brings on Crystal Dynamics to help develop its Perfect Dark reboot

Esports5 days ago

CS:GO Riptide Case: Full List of New Skins

Esports4 days ago

How to check Diablo 2: Resurrected server status

Esports5 days ago

Some players unable to claim Pokémon UNITE mobile pre-registration rewards due to new error

Esports3 days ago

Best Stats for the Druid in Diablo II: Resurrected

Blockchain4 days ago

United States Infrastructure Bill Brings Cardano Billionaire to Washington.

Esports5 days ago

How to redeem Operation Riptide’s rewards in CS:GO

Cyber Security4 days ago

Apple bans Epic Games from App Store

Energy5 days ago

Carbon Nanotubes Market size worth $ 20.31 Billion, Globally, by 2028 at 17.27% CAGR: Verified Market Research®

Esports4 days ago

Failed to Enter Game, Character Could Not be Found: How to Fix Error in Diablo II: Resurrected

Esports2 days ago

NBA 2K22 ‘Meet the Designers’ Quest Guide: How to Complete